FDA-Approved MedicationUpdated November 2026

Wegovy Guide

Wegovy is the brand-name formulation of semaglutide, FDA-approved for chronic weight management, cardiovascular risk reduction, and (since August 2025) noncirrhotic MASH with liver fibrosis. Developed by Novo Nordisk, it is available as a once-weekly subcutaneous injection (0.25–2.4 mg, or up to 7.2 mg Wegovy HD for weight reduction) and — added to the FDA label in December 2025 — a once-daily oral tablet (1.5–25 mg) for cardiovascular risk reduction or weight reduction in adults.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

At a Glance

Generic NameSemaglutide
Brand NamesWegovy
FDA StatusFDA-approved for chronic weight management in adults with obesity or overweight with comorbidity (June 2021); cardiovascular risk reduction in adults with established CVD (March 2024); weight reduction in pediatric patients aged 12+ (Dec 2022); noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (August 2025); and — since December 2025 — an oral tablet form for cardiovascular risk reduction or weight reduction in adults, alongside the original injection[1]
Approval DateJune 4, 2021[1]

How Wegovy Works

Wegovy mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake. The injection reaches a maintenance dose of 1.7–2.4 mg weekly (up to 7.2 mg for weight reduction if more loss is needed); the oral tablet (added December 2025) reaches a 25 mg once-daily maintenance dose through its own 90-day titration — both deliver the same active ingredient, semaglutide, just via a different route and schedule.[2]

Dosing Schedule — Injection

Wegovy uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–40.25mg/week
Weeks 5–80.5mg/week
Weeks 9–121.0mg/week
Weeks 13–161.7mg/week
Week 17+1.7–2.4mg/week (maintenance; varies by indication, up to 7.2mg for weight reduction)

Dosing Schedule — Tablet (approved Dec 2025)

Days 1–301.5mg/day
Days 31–604mg/day
Days 61–909mg/day
Day 91+25mg/day (maintenance)

Side Effects

Common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache, fatigue. Side effects typically peak during dose escalation and diminish within 4–8 weeks. Serious (rare): pancreatitis, gallstones, kidney injury, heart rate increase.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

The STEP-1 trial showed Wegovy users lost an average of 14.9% of body weight (about 34 lbs) over 68 weeks compared to 2.4% in placebo. The SELECT cardiovascular outcomes trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events in obese patients with established CVD.[2][3][4]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Wegovy

These telehealth providers offer access to semaglutide with online consultations and home delivery. Before you book a consult, our guide to getting Wegovy online walks through eligibility, the prescriber visit, and what legitimate pharmacy fulfillment looks like.

8.3/ 10
Partner

Found

Best for: medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

★★★★☆4.2/5

Editorial score · methodology

$289/4 wkssemaglutide
billed per 4 weeks
$359/4 wkstirzepatide
billed per 4 weeks
CompoundedSemaglutideTirzepatideOrforglipron
Get StartedRead full Found review →
8.1/ 10
Partner

RxSpan MD

Best for: physician-led, pharmacy-transparent compounded GLP-1 with brand-name options

★★★★☆4.1/5

Editorial score · methodology

$249/mosemaglutide
$329/motirzepatide
CompoundedSemaglutideTirzepatideGHK-CuGlutathioneLegitScript Verified
Get StartedRead full RxSpan MD review →
8.0/ 10
Partner

Sesame Care

Best for: Brand-name GLP-1s at cash prices, no compounding

★★★★☆4/5

Editorial score · methodology

$149/mosemaglutide
see plan details
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Sesame Care review →
8.0/ 10
Partner

ShedRx

Best for: compounded GLP-1 as an injection, drops or lozenges, with lower rates on 6- and 12-month plans

★★★★☆4/5

Editorial score · methodology

$199/mosemaglutide
plan-length pricing
$279/motirzepatide
“starting at” price
CompoundedSemaglutideTirzepatideOrforglipronGHK-Cu
Get StartedRead full ShedRx review →
7.9/ 10
Partner

GobyMeds

Best for: no-membership, no-auto-renew compounded GLP-1 orders, from about $99/mo on a 3-month bundle

★★★★☆4/5

Editorial score · methodology

$169/mosemaglutide
“starting at” price
$299/motirzepatide
“starting at” price
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full GobyMeds review →
7.7/ 10
Partner

Ro

Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

★★★★☆3.9/5

Editorial score · methodology

$149/mosemaglutide
+ required membership
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Ro review →

Each provider's lowest ongoing monthly cash price for Wegovy, sorted cheapest first (no copays, membership fees or intro offers). Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[7]. Prices may vary based on dose.

ProviderFrom (ongoing)
Amazon One Medical$149/momedication billed separatelyVisit
GoodRx$149/morises with doseVisit
Heally$149/mo“starting at” priceVisit
Healthspan$149/mo+ required membershipVisit
Hers$149/mo+ required membershipVisit
Hims$149/mo+ required membershipVisit
HuHealth$149/mosee plan detailsVisit
Imbue Health$149/mo+ required membershipVisit
LifeMD$149/mo+ required membershipVisit
Measured$149/mo+ required membershipVisit
Médetone$149/mo+ required membershipVisit
NovoCare Pharmacy$149/morises with doseVisit
Ro$149/mo+ required membershipVisit
Sesame Care$149/mosee plan detailsVisit
ShedRx$149/mo+ required membershipVisit
PreventiveMD$198/mo“starting at” priceVisit
Found$199/mostarting doseVisit
Alloy$248/mostarting doseVisit
Aspire Health$248/moper 4 weeksVisit
Phoenix NP$248/moper 4 weeksVisit
SkinnyRx$248/mo“starting at” priceVisit
Maximus$250/mostarting doseVisit
Healthicare$269/mosee plan detailsVisit
Mochi Health$278/mo+ added feeVisit
GOAL.MD$294/mosee plan detailsVisit
Good Girl Rx$297/moVisit
eMed$300/mo+ required membershipVisit
AgelessRx$349/moafter intro offerVisit
Rex MD$349/moVisit
PlushCare$399/mo+ required membershipVisit
WePeptideRx$399/moper 4 weeksVisit
Pallas Health$499/moper 4 weeksVisit
Tuyo Health$499/mo+ required membershipVisit
NuDay Rx$990/moVisit
Vital Edge$990/moVisit
RxSpan MD$1,349/moVisit
Trimrose$1,349/mostarting doseVisit
Corsica Health$1,499/mosee plan detailsVisit
altRX$1,579/moVisit
DudeMeds$1,585/mo3-month plan rateVisit
HeliMeds$1,599/moper 4 weeksVisit
Effecty$1,600/mosee plan detailsVisit
GobyMeds$1,695/moVisit
Tomorrow$1,699/moVisit
OrderlyMeds$1,839/mosee plan detailsVisit
BiltRx$1,849/mo+ consult feeVisit
Bon Health$1,869/mo+ added feeVisit
myRocky$1,869/moVisit
Concierge MD LA$1,999/moVisit

Short-form verdict pages comparing Wegovy to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

See all drug-vs-drug verdicts, or compare every weight loss medication we cover.

Endpoint-by-endpoint breakdowns of the trials that shaped the Wegovy label, with primary-source numbers and FAQs.

STEP-1
STEP-1 is the pivotal NEJM trial that established once-weekly semaglutide 2.4 mg as a category-defining obesity drug. This deep-dive walks through every reported endpoint — body weight, waist, blood pressure, hs-CRP, HbA1c, IWQOL-Lite-CT, SF-36 — with the actual numbers from the Wilding 2021 publication and the ClinicalTrials.gov results posting, plus adverse-event incidence and FAQs about run-in, dose tolerance, and durability after treatment ends.
Phase 3 · N=1,961 · Last verified November 2026
SELECT
SELECT (Lincoff 2023, NEJM, PMID 37952131) was the first cardiovascular-outcomes trial of a GLP-1 receptor agonist run in adults with obesity but no diabetes. Across 17,604 participants followed a mean 39.8 months, weekly semaglutide 2.4 mg reduced the primary three-point MACE composite by 20% versus placebo. The result moved semaglutide from a weight-loss drug into the cardioprotection conversation and underpinned Wegovy's March 2024 FDA label expansion to reduce MACE risk in adults with obesity and established cardiovascular disease.
3 · N=17,604 · Last verified November 2026
STEP-4
STEP-4 is the canonical "if I stop, will the weight come back" trial. After a 20-week open-label run-in on semaglutide 2.4 mg during which participants lost a mean 10.6% of body weight, 803 responders were randomized 2:1 to either continue weekly semaglutide for 48 more weeks or switch to placebo. Those who continued lost another 7.9% on top of run-in losses. Those switched to placebo regained 6.9% over the same 48 weeks — a 14.8 percentage-point swing. Waist circumference, systolic blood pressure, and SF-36 physical-functioning scores all moved in the same direction: maintained on drug, partially reversed off it. STEP-4 is the trial that turned obesity drugs into chronic-disease therapy in the regulatory and clinical conversation.
Phase 3a · N=803 · Last verified November 2026
STEP-2
STEP-2 is the companion to STEP-1 — the pivotal trial that established once-weekly semaglutide 2.4 mg for adults with overweight or obesity who also have type 2 diabetes. Novo Nordisk randomized 1,210 adults with BMI ≥27 and HbA1c 7-10% to semaglutide 2.4 mg, semaglutide 1.0 mg (the Ozempic dose), or matching placebo for 68 weeks, with monthly lifestyle counseling in every arm. Mean weight loss at week 68 was −9.6% on the 2.4 mg dose versus −7.0% on 1.0 mg and −3.4% on placebo, with HbA1c falling by 1.6 percentage points on both active doses. The trial provided the regulatory case that Wegovy works in patients with T2D and informed why the obesity-dose effect on weight is blunted, but not erased, by diabetes.
Phase 3 · N=1,210 · Last verified November 2026

Real patient questions about Wegovy pulled from named subreddits and answered with peer-reviewed trial data.

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Wegovy Dose Ladder: Injection & New Oral Tablet (2026 Cheat Sheet)
FDA-label Wegovy titration on one page — the injection ladder, the new once-daily oral tablet added to the label in 2026, indication-specific maintenance doses, missed-dose rules for both forms, and the side-effect red flags that mean call your doctor. DailyMed-sourced, label revised June 2026.
6 min read · Last verified November 2026
GLP-1 Injection Site Rotation: 8-Week Cheat Sheet (2026)
Wegovy, Ozempic, Zepbound, and Mounjaro all share the same three FDA-approved injection sites: abdomen, front of thigh, and back of upper arm. Reusing the same spot week after week causes lipohypertrophy, thickened fatty tissue that absorbs the drug erratically, leaving appetite suppression and weight-loss results inconsistent. This cheat sheet maps the approved sites, gives an 8-week rotation example, and lists the technique mistakes that send users back to the prescriber.
4 min read · Last verified November 2026
Saxenda Dose Ladder (2026 Cheat Sheet)
FDA-label Saxenda titration on one page — the 5-step daily ladder, the 3-day re-titration rule, the red-flag side effects that mean call the prescriber, and the practical case for moving to a weekly GLP-1. DailyMed-sourced, current 2026.
5 min read · Last verified November 2026
GLP-1 to GLP-1 Switching (2026 Cheat Sheet)
Wegovy → Zepbound, Ozempic → Mounjaro, Saxenda → Wegovy: FDA labels do not address head-to-head switching directly. Starting-dose matrix, wait times between drugs, and red flags during the transition on one scannable page.
5 min read · Last verified November 2026

Curated lists of the highest-impact peer-reviewed studies on Wegovy and related GLP-1 drugs. Every PMID is checked against its PubMed record.

Top 10 PubMed Studies on Semaglutide for Weight Loss (2026)
Ten peer-reviewed semaglutide weight-loss studies anchored to the STEP program (STEP-1 to STEP-8, STEP-TEENS, STEP-HFpEF), the SELECT cardiovascular outcomes trial, and OASIS-1 high-dose oral. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top 10 PubMed Studies on GLP-1 Cardiovascular Outcomes (2026)
Ten landmark cardiovascular outcomes trials that established GLP-1 receptor agonists as cardioprotective drugs beyond glycemic control. Covers MACE reduction in type 2 diabetes (LEADER, SUSTAIN-6, REWIND, AMPLITUDE-O, PIONEER 6), the SURPASS-CVOT tirzepatide-versus-dulaglutide trial, the SELECT paradigm-shift in obesity without diabetes, kidney outcomes in FLOW, heart failure in STEP-HFpEF, and the foundational neutral ELIXA post-ACS trial. Each entry includes the PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top 10 PubMed Studies on GLP-1 Agonists for MASH and MASLD (2026)
Ten peer-reviewed studies that built the GLP-1-class case in metabolic-dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease (MASLD, formerly NAFLD). Covers SYNERGY-NASH (tirzepatide phase 2), the ESSENCE phase 3 semaglutide trial, the Newsome 2020 phase 2 semaglutide NASH biopsy trial, the survodutide and retatrutide phase 2 readouts, the foundational LEAN liraglutide trial, semaglutide in MASH-related cirrhosis, the pemvidutide IMPACT phase 2b trial, the SURPASS-3 MRI liver-fat substudy of tirzepatide, and the 2025 Mantovani class-level meta-analysis. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top 10 PubMed Studies on Compounded GLP-1 Safety and Quality (2026)
Ten peer-reviewed papers that document the safety, quality, and regulatory landscape of compounded GLP-1 receptor agonists. No published head-to-head bioequivalence randomized trial has compared compounded semaglutide or tirzepatide against brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. The literature instead consists of FAERS and EudraVigilance pharmacovigilance studies, poison-control case series, mass-spectrometry impurity analyses, an FDA-shortage 503A-vs-503B regulatory review, the 2025 American Diabetes Association statement, a direct-to-consumer market analysis, and clinical-guidance reviews. Each entry includes PMID, source journal, study design, and editorial summary explaining what the paper documents and what it does not establish.
10 ranked papers · Last verified November 2026

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Switching From Semaglutide to Tirzepatide: Washout, Dose & What to Expect (2026)
Switching from semaglutide to tirzepatide: the short 3-7 day timing gap, why you restart at 2.5 mg (no dose-matching, no conversion chart), and what to expect. Prescriber-led.
9 min read6 citations
How to Inject Semaglutide: A Step-by-Step Guide (Sites, Technique & Mistakes to Avoid) (2026)
How to inject semaglutide step by step: prefilled pen vs compounded vial, injection sites, rotation, the right angle and technique, sharps disposal, and mistakes to avoid.
8 min read4 citations
Best Time of Day to Take Semaglutide: Morning or Night? (2026)
Injectable semaglutide (Ozempic, Wegovy) can be taken any time of day, with or without food — same day each week is what matters. Rybelsus is the strict morning exception.
6 min read5 citations
What 3 Ingredients Mimic Ozempic? (Honest Answer: None Do) (2026)
No combination of 3 ingredients mimics Ozempic. We grade berberine, soluble fiber (oatzempic), and apple cider vinegar honestly against semaglutide's ~15% weight loss.
9 min read5 citations
Do You Need Labs for Semaglutide? Bloodwork Before & During Treatment (2026)
Semaglutide has no FDA-label requirement for routine lab monitoring, but baseline bloodwork is strongly advisable. What labs, why, how often, and getting it without labs.
9 min read5 citations
Why Do So Many People Quit Ozempic? The Real Reasons (2026)
Most people quit Ozempic within a year. The real reasons — GI side effects, $1,000+/mo cost, plateaus, regain fear — and what to do instead of quitting. Real-world evidence, not anecdotes.
9 min read4 citations

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity or overweight with comorbidity (June 2021); cardiovascular risk reduction in adults with established CVD (March 2024); weight reduction in pediatric patients aged 12+ (Dec 2022); noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults (August 2025); and — since December 2025 — an oral tablet form for cardiovascular risk reduction or weight reduction in adults, alongside the original injection
Among the 49 providers in the cost comparison table above, Wegovy's lowest ongoing monthly cash price is $149 and the highest is $1,999, depending on provider, form and dose. These are medication prices only — copays, membership fees and intro offers are excluded. Always check for manufacturer savings programs.
Common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache, fatigue. Side effects typically peak during dose escalation and diminish within 4–8 weeks. Serious (rare): pancreatitis, gallstones, kidney injury, heart rate increase.
Wegovy requires a prescription from a licensed healthcare provider. You can get it through your primary care doctor, endocrinologist, or a telehealth platform. The telehealth providers listed above prescribe it online.
Sources & methodology (as of November 2026)
  1. 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  4. 4.SELECT Trial — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (Lincoff AM et al.)— New England Journal of Medicine.PMID: 37952131.
  5. 5.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  6. 6.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  7. 7.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.